Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF class 2||pancreatic cancer||predicted - sensitive||Exarafenib||Preclinical - Cell culture||Actionable||In a preclinical study, Exarafenib (KIN-2787) treatment led to inhibition of tumor growth in a pancreatic cell line xenograft model harboring a BRAF class 2 mutation (J of Clin Oncol 39, no. 15_suppl (May 20, 2021) 3116-3116).||detail...|
|PubMed Id||Reference Title||Details|
|The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models.||Full reference...|